|
Affiliation |
Hospital Division of Blood Transufusion |
|
Mail Address |
|
NARA Miho
|
|
|
Graduating School 【 display / non-display 】
-
-2004.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2013.03
Akita University Graduate School, Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2023.06-Now
Akita University Hospital Division of Blood Transufusion Lecturer
-
2021.10-2023.05
Akita University Hospital Lecturer
-
2013.11-2021.09
Akita University Hospital Internal MedicineⅢ Assistant Professor
Research Areas 【 display / non-display 】
-
Life Science / Hematology and medical oncology
Thesis for a degree 【 display / non-display 】
-
Bortezomib Reduces the Tumorigenicity of Multiple Myeloma via Downregulation of Upregulated Targets in Clonogenic Side Population Cells.
Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A, Kume M, Hatano Y, Takahashi N, Iida S, Sawada K, Tagawa H.
PLoS One. 2013.03
Domestic Co-author
Research Achievements 【 display / non-display 】
-
Sato H.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 90 ( 3 ) 279 - 284 2022.09 [Refereed]
Research paper (journal) Domestic Co-author
-
Kameda K.
Leukemia ( Leukemia ) 36 ( 5 ) 1361 - 1370 2022.05 [Refereed]
Research paper (journal) Domestic Co-author
-
Yanada M.
Bone Marrow Transplantation ( Bone Marrow Transplantation ) 57 ( 1 ) 78 - 82 2022.01 [Refereed]
Research paper (journal)
-
Effect of Itraconazole on the Concentrations of Tacrolimus and Cyclosporine in the Blood of Patients Receiving Allogeneic Hematopoietic Stem Cell Transplants.
Miho Nara, Naoto Takahashi, Masatomo Miura, Takenori Niioka, Hideaki Kagaya, Naohito Fujishima, Hirobumi Saitoh, Yoshihiro Kameoka, Hiroyuki Tagawa, Makoto Hirokawa, and Kenichi Sawada.
Eur J Clin Pharmacol. 2013.01 [Refereed]
Research paper (journal) Domestic Co-author
-
FUJITA Nanako, YAMASHITA Takaya, ABE Fumito, NARA Miho, YOSHIOKA Tomoko, KOGA Hiroshi, ISHII Norito, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 64 ( 2 ) 107 - 112 2023
<p>Haploidentical allogeneic hematopoietic stem cell transplantation from her brother was performed on a 41-year-old lady with no prior history of pemphigoid to treat recurrent AML. On day 59 following transplantation, she experienced esophageal stenosis. During immunosuppressive therapy for graft vs. host disease, this condition was controlled with periodic esophageal dilatation (GVHD). Her esophageal stricture, which required periodic dilatation, grew worse after she stopped immunosuppressive therapy because of recurrent AML. The esophageal mucosa was easily hemorrhagic and desquamative. Histologic analysis revealed that the squamous cell layers had been divided. Indirect immunofluorescence was negative for IgG and positive for IgA on the epidermal layers, while direct immunofluorescence showed a linear deposition of IgG on the basement membrane zone. It was determined through immunoblotting utilizing recombinant protein of BP180 C-terminal domain that both IgG and IgA antibodies were present, supporting the diagnosis of mucous membrane pemphigoid with anti-BP180. After allogeneic transplantation, basal epidermal cell destruction by GVHD may result in autoimmune blistering disorders, which expose basement membrane proteins and antigen presentation. A similar mechanism could apply to our situation. For rare GVHD cases, a thorough histological diagnosis is required.</p>
-
Prevalence of organ symptoms in allo-HCT survivors and their impact on work and daily life
Matsuura Tomoko, Kurosawa Saiko, Yamaguchi Takuhiro, Mori Ayako, Mori Takehiko, Tanaka Masatsugu, Kondo Tadakazu, Sakamoto Shuko, Fujii Nobuharu, Ichinohe Tatsuo, Nara Miho, Maeda Tomoya, Fujisawa Shin, Nawa Yuichiro, Nakamura Yukinori, Minamiguchi Hitoshi, Onishi Yasushi, Takano Kuniko, Takahashi Miyako, Fukuda Takahiro
Japanese Journal of Transplantation and Cellular Therapy ( Japanese Society for Transplantation and Cellular Therapy ) 10 ( 4 ) 172 - 182 2021
<p> We conducted a nationwide cross-sectional questionnaire study to assess the prevalence of organ symptoms in allogeneic hematopoietic cell transplantation (allo-HCT) survivors and its impact on work and daily life. We targeted allo-HCT survivors employed at diagnosis, aged 20-64 at survey, and who survived≥2 years without relapse. The questionnaire included the presence or absence of 34 organ symptoms and their impact on work and daily life, as well as patient-, HCT-, and work-related factors. A total of 841 participants who were working at the time of the survey were included in the analysis (response rate, 60%). Ninety-two percent of participants had at least one symptom; the skin (78%), joints/muscles (72%), eyes (61%), and psychological health (44%) were frequently affected. Multivariable logistic regression analysis of the impact of symptoms on work showed that different job types were independently associated with different symptoms: indoor/physical work (medical care staff, etc.) with itching, dry eyes, restricted joint mobility; outdoor/light duty (sales staff, etc.) with thinning of hair and depressive state; and outdoor/physical work (construction, etc.) with dazzling. Our findings indicated that it may be effective to provide individual intervention and education that take into consideration both survivors' symptoms and their work/life conditions.</p>
-
TAFRO Syndrome with Bilateral Adrenal Hemorrhage
Ito Fumiko, Kameoka Yoshihiro, Nara Miho, Ubukawa Kumi, Fujishima Masumi, Yoshioka Tomoko, Fujishima Naohito, Takahashi Naoto
Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine ) 106 ( 2 ) 288 - 294 2017
-
FUJISHIMA Masumi, FUJISHIMA Naohito, KITADATE Akihiro, GUO Yongmei, WATANABE Atsushi, UBUKAWA Kumi, NARA Miho, YOSHIOKA Tomoko, KAMEOKA Yoshihiro, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 58 ( 7 ) 743 - 748 2017
<p>A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.</p>